Methadone

CHEMBL651 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

309.4 g/mol

LogP

3.9

Phase

4

A long-acting opioid used to treat opioid use disorder by reducing withdrawal symptoms and cravings, and also used to manage severe chronic pain. It must be taken under close medical supervision due to its risk of dependence and potential for serious side effects.

Molekularmasse

309,4000 g/mol

LogP

3,90

TPSA

20,30 Å²

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Psychiatry Respiratory Disease Pain Management Non-Small Cell Lung Cancer Osteoporosis Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Generalized Anxiety Disorder Infectious Disease Gastroesophageal Reflux Disease Inflammatory Bowel Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Obesity Lymphoma Major Depressive Disorder Breast Cancer Chronic Pain HIV/AIDS Hepatitis C Tuberculosis Prostate Cancer Colorectal Cancer Leukemia

Wirkmechanismus

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1

InChI

InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3

Molecular Formula

C21H27NO

HBD / HBA

- / 2

Rotierbare Bindungen

7

Schwere Atome

23

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A long-acting opioid used to treat opioid use disorder by reducing withdrawal symptoms and cravings, and also used to manage severe chronic pain. It must be taken under close medical supervision due to its risk of dependence and potential for serious side effects.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Methadone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL651. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 4095. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Methadone auf PillFYI

Struktur

Schnelldaten

Formel: C21H27NO
Synonyme: 7

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.